GlaxoSmithKline Pharmaceuticals Intrinsic Value
GlaxoSmithKline Pharmaceuticals intrinsic value. GlaxoSmithKline Pharmaceuticals (GLAXO) median intrinsic value is ₹1124.26 from 10 valuation models (range ₹543–₹2280), vs current price ₹2713.40 — -58.6% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse GlaxoSmithKline Pharmaceutical shareholding analysis to track promoter, FII and institutional holdings.
GLAXO Valuation Methods Summary — DCF, Graham Number & P/E
GlaxoSmithKline Pharmaceuticals intrinsic value across 10 models vs current price ₹2713.40 — upside/downside and value range per method. Browse GLAXO cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1745.04 | ₹1396.03 - ₹2094.05 | -35.7% | EPS: ₹79.32, Sector P/E: 22x |
| Book Value Method | asset | ₹542.68 | ₹488.41 - ₹596.95 | -80.0% | Book Value/Share: ₹134.14, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹814.02 | ₹732.62 - ₹895.42 | -70.0% | Revenue/Share: ₹297.28, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1124.26 | ₹1011.83 - ₹1236.69 | -58.6% | EBITDA: ₹1900.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1085.36 | ₹868.29 - ₹1302.43 | -60.0% | CF Growth: 2.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹814.02 | ₹732.62 - ₹895.42 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1225.49 | ₹1102.94 - ₹1348.04 | -54.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1356.70 | ₹1221.03 - ₹1492.37 | -50.0% | ROE: 59.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹814.02 | ₹732.62 - ₹895.42 | -70.0% | EPS: ₹79.32, BVPS: ₹134.14 |
| Dividend Yield Method | dividend | ₹2280.00 | ₹2052.00 - ₹2508.00 | -16.0% | DPS: ₹57.00, Target Yield: 2.5% |
GLAXO Intrinsic Value vs Market Price — All Valuation Models
GlaxoSmithKline Pharmaceuticals fair value range ₹543–₹2280 vs current market price ₹2713.40 across 10 valuation models. For current market price and key ratios, visit GlaxoSmithKline Pharmaceutical share price today.
GLAXO Intrinsic Value Analysis — Undervalued or Overvalued?
GlaxoSmithKline Pharmaceuticals median intrinsic value ₹1124.26, current price ₹2713.40 — Trading Above Calculated Value by 58.6%, margin of safety -100.0%.
What is the intrinsic value of GLAXO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of GlaxoSmithKline Pharmaceuticals (GLAXO) is ₹1124.26 (median value). With the current market price of ₹2713.40, this represents a -58.6% variance from our estimated fair value.
The valuation range spans from ₹542.68 to ₹2280.00, indicating ₹542.68 - ₹2280.00.
Is GLAXO undervalued or overvalued?
Based on our multi-method analysis, GlaxoSmithKline Pharmaceuticals (GLAXO) appears to be trading above calculated value by approximately 58.6%.
GLAXO Financial Health — Key Ratios vs Industry Benchmarks
GlaxoSmithKline Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 59.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.16x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
GLAXO Cash Flow Quality — Operating & Free Cash Flow
GlaxoSmithKline Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹903 Cr | ₹903 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,290 Cr | ₹1,267 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹582 Cr | ₹582 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹484 Cr | ₹484 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹811 Cr | ₹608 Cr | Positive Free Cash Flow | 8/10 |